Did you mean 115 10 9?
Displaying drugs 2451 - 2475 of 3551 in total
Amlitelimab
Amlitelimab is under investigation in clinical trial NCT06181435 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)).
Investigational
TK-112690
Investigational
RGX-181
RGX-181 consists of an adeno-associated virus serotype 9 (AAV9) vector designed to deliver the soluble lysosomal enzyme tripeptidyl peptidase I (TPP1) gene. Developed by REGENXBIO, it is being investigated for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease.
Investigational
Matched Description: … RGX-181 consists of an adeno-associated virus serotype 9 (AAV9) vector designed to deliver the soluble …
Loprazolam
Loprazolam is an imidazobenzodiazepine with anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties. It is indicated for the short-term treatment of insomnia including difficulty in falling asleep and/or frequent nocturnal awakenings. Loprazolam is recommended as a short-term therapy only, due to adverse events associated with the drug including dependence...
Experimental
Matched Iupac: … ^{2,6}]tetradeca-1(10),5,8,11,13-pentaen-3-one ... (4Z)-9-(2-chlorophenyl)-4-[(4-methylpiperazin-1-yl)methylidene]-12-nitro-2,5,8-triazatricyclo[8.4.0.0 …
Pelabresib anhydrous
Investigational
Matched Iupac: … 2-[(7S)-9-(4-chlorophenyl)-3-methyl-5-oxa-4,8-diazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),2(6),3,8,11,13 …
Finotonlimab
Finotonlimab is under investigation in clinical trial NCT04560894 (SCT-I10A Plus SCT510 Versus Sorafenib as First-line Therapy for Advanced Hepatocellular Carcinoma).
Investigational
Valethamate
Experimental
Matched Mixtures name: … EPIDOSIN COMPOSITUM 10 MG AMPUL, 3 ADET …
Matched Products: … EPIDOSIN 10 MG SUPPOZITUAR, 6 ADET …
Matched Products: … EPIDOSIN 10 MG SUPPOZITUAR, 6 ADET …
NV1020
NV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.
Investigational
AGRO100
AGRO100 is an oligonucleotide that functions as an aptamer and binds to nucleolin, a protein found intranuclear in all cells, but uniquely expressed on the surface of tumor cells. Such binding leads to internalization of the complex, and a strong anti-proliferative response in the tumor cell.
Pre-clinical testing demonstrates that...
Investigational
LX1031
LX1031 is an orally-dosed drug candidate for irritable bowel syndrome and other gastrointestinal disorders. LX1031 was generated by Lexicon medicinal chemists, and its target was internally identified as a key control point for the regulation of peripheral serotonin levels. LX1031 is designed to act locally in the gastrointestinal tract by...
Investigational
AP1081
A transdermal gel containing ethinyl estradiol and norelgestromin being investigated by Antares Pharma for use as a female contraceptive.
Investigational
NLX-P101
NLX-P101, gene therapy is developed by Neurologix to treat Parkinson’s disease. The gene is glutamic acid decarboxylase (GAD), whose product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA), and targets the subthalamic nucleus (STN), which is overactive in patients with Parkinson’s disease. NLX-P101 is being evaluated as...
Investigational
TG1024
Investigational
GSK-1059615
GSK1059615 has been used in trials studying the treatment of Lymphoma, Solid Tumours, Endometrial Cancer, Solid Tumor Cancer, and Metastatic Breast Cancer.
Investigational
GSK-1004723
Gsk1004723 has been investigated for the treatment of Allergic Rhinitis and Rhinitis, Allergic, Seasonal.
Investigational
BZL101
BZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact.
Investigational
Biomed 101
Biomed 101 is investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma. Biomed 101 is a solid. Biomed 101 binds to the leukotriene B4 receptor, but does not affect interleukin-2 antitumor activity.
Investigational
ICA-105665
ICA-105665 is a novel small molecule compound for the treatment of epilepsy. It is a novel opener of the KCNQ ion channel which in preclinical studies has demonstrated a broad spectrum of activity in models of epilepsy. In addition, ICA-105665 has also demonstrated activity in certain models of neuropathic pain.
Investigational
JAG101
Investigational
Yttrium Y-90 epratuzumab tetraxetan
Investigational
Xevinapant
Investigational
Displaying drugs 2451 - 2475 of 3551 in total